"Temporarily on hold," Musk tweeted Friday morning.
The women-first dating service had 24% revenue growth in Q1.
The company posted $208 million in revenue for the first quarter.
BMY will pay BBIO $90 million in upfront cash.
The companies are facing over 3,500 opioid-related lawsuits.
Growth was driven by its Evernorth health services unit.
The company is developing treatments for serious genetic diseases, with an initial focus on neuromuscular diseases.
The stock was priced at $18 per share, off a filing range of $21 - $24.
The company is waiting on FDA review of its lead product candidate.
Biogen will also halt marketing of Aduhelm.